There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. One drug I've been keeping a close eye on ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish ...

The lawsuits follow an announcement by Novo Nordisk that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers’ sales and “deceptive” marketing of the ...

Evotec SE (NASDAQ: EVO) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 25, the company said it would participate in the NURTuRE-AKI consortium to investigate ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts parsing the data presented at the American Diabetes Association annual meeting ...

PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy ® (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers, a ...